His primary areas of study are Internal medicine, Transplantation, Surgery, Gastroenterology and Hematopoietic stem cell transplantation. Fludarabine, Leukemia, Regimen, Busulfan and Cyclophosphamide are subfields of Internal medicine in which his conducts study. Borje S. Andersson has researched Transplantation in several fields, including Immunology, Cord blood, Pathology, CD34 and Preparative Regimen.
His work in Surgery covers topics such as Bone marrow which are related to areas like Radiation therapy. His Gastroenterology research includes themes of Tacrolimus, Cumulative incidence, Allogeneic transplantation, Lymphoma and Transplantation Conditioning. His Hematopoietic stem cell transplantation study combines topics from a wide range of disciplines, such as Progenitor cell, Immunosuppression and Graft-versus-host disease.
Internal medicine, Transplantation, Busulfan, Surgery and Gastroenterology are his primary areas of study. Internal medicine and Oncology are commonly linked in his work. His research in Transplantation tackles topics such as Leukemia which are related to areas like Myeloid.
His Busulfan research is multidisciplinary, incorporating perspectives in Pharmacokinetics, Pharmacology, Myeloid leukemia, Gemcitabine and Clofarabine. His Surgery research is multidisciplinary, incorporating elements of Transplantation Conditioning and Bone marrow. His study explores the link between Gastroenterology and topics such as Cumulative incidence that cross with problems in Univariate analysis.
Borje S. Andersson spends much of his time researching Internal medicine, Busulfan, Transplantation, Oncology and Hematopoietic stem cell transplantation. His Internal medicine research includes elements of Gastroenterology and Surgery. He has included themes like Clinical trial, Melphalan, Gemcitabine, Fludarabine and Clofarabine in his Busulfan study.
Borje S. Andersson interconnects Chemotherapy regimen, Blast Count, Randomized controlled trial, Hazard ratio and Bone marrow in the investigation of issues within Transplantation. Borje S. Andersson focuses mostly in the field of Oncology, narrowing it down to topics relating to Leukemia and, in certain cases, Myeloid. His research investigates the connection between Hematopoietic stem cell transplantation and topics such as Immunology that intersect with problems in Hemorrhagic cystitis.
Borje S. Andersson mainly focuses on Internal medicine, Transplantation, Hematopoietic stem cell transplantation, Busulfan and Oncology. He combines subjects such as Gastroenterology and Surgery with his study of Internal medicine. In his study, European LeukemiaNet is inextricably linked to Transplantation Conditioning, which falls within the broad field of Surgery.
His Transplantation research integrates issues from Randomized controlled trial, Intention-to-treat analysis, Myelodysplastic syndromes, Hazard ratio and Comorbidity. His studies in Hematopoietic stem cell transplantation integrate themes in fields like Incidence, Immunology, Bone marrow and Graft-versus-host disease. His Busulfan study combines topics from a wide range of disciplines, such as Mucositis, Pharmacokinetics, Melphalan, Regimen and Fludarabine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien.
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
I F Khouri;M Keating;M Körbling;D Przepiorka.
Journal of Clinical Oncology (1998)
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang.
Allogeneic Blood Stem Cell Transplantation for Refractory Leukemia and Lymphoma: Potential Advantage of Blood Over Marrow Allografts
M Korbling;D Przepiorka;YO Huh;H Engel.
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang.
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
Marcos De Lima;Athanasios Anagnostopoulos;Mark Munsell;Munir Shahjahan.
Cord-blood engraftment with ex vivo mesenchymal-cell coculture.
Marcos J.G. de Lima;Ian McNiece;Simon N. Robinson;Mark Munsell.
The New England Journal of Medicine (2012)
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
D. Przepiorka;N. A. Kernan;C. Ippoliti;E. B. Papadopoulos.
Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.
N T Ueno;G Rondón;N Q Mirza;D K Geisler.
Journal of Clinical Oncology (1998)
Tumor necrosis factor-α blockade for the treatment of acute GVHD
Daniel Couriel;Rima Saliba;Krystal Hicks;Cindy Ippoliti.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: